Ken I don't know if cancelling the reserve is a good, bad or inevitable thing. I assume it gets applied against the accumulated losses, meaning Softbank are more likely to buy the company as a going concern. Their days of over spending on acquisitions have gone, but hopefully there will enough left over to give Molten a feed.
The reason I haven't sold any is that by my reckoning institutions now hold north of 95% of shares, so there is very little to play with. If they hold tight it won't drop much. If they keep accumulating the only way is up.
Steph I think nice risk is still about right and one I am comfortable with. I think some of the portfolio are having trouble growing despite having the funds as I see the same technical and market expansion vacancies unfilled sometimes after many months, the exception still being Revolut.
There will be lots of general waffle about business strategy using AWS and other cloud based services. There won't be be much more on cost reductions, already said it all, more about growth. I don't know what else you would expect from someone who came from AWS.
My bad. I was also adding in the biomass fermentation expansions in the US, which skewed it a lot. For precision I agree not much at scale in the US mainly pilot size. Not to say there are no other options, Perfect Day bought an Indian contract producer rather than build in the US or keep using Olon in Italy to bring down costs.
People are already consuming the products from precision fermentation globally , they just don't recognise it. Aijinmoto's turnover in this biotech area is 200b yen per year growing at 20% pa. But I take with a grain of salt the claim that Liberation labs has open access to unmet demand. Maybe I'm wrong but a quick google shows a number of other large plants at a similar stage of build.
Don't hold your breath. They didn't get anything worthwhile the last time they were up against them for misleading advertising and the firm was only asked to take more care, no injunction. This case was filed a month ago so hopefully won't have to wait too long for an outcome. Unfortunately I can't source the filing. UK is hopeless as most other countries there is public access to filings real time, so you have a better idea of the arguments.
Actually the old option holder Soligenix is a prime candidate for a Polb back door listed, in very poor financial health with but a bucket load of approved orphan drugs and completed phase 2s. It looks like they let the option laspse from lack of money rather than lack of potential.